drugset
drugset / Trial / NCT02208934

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

NCT02208934 ↗

Phase 1 Completed 32 enrolled Sant Pau Research Institute Palo Biofarma, S.L · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers

Timeline

Start
2014-09
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PBF-999 Small molecule 5 mg Oral
Subject PBF-999 Small molecule 10 mg Oral
Subject PBF-999 Small molecule 20 mg Oral
Subject PBF-999 Small molecule 40 mg Oral

Indications

Huntington disease